Complement Therapeutics Website, Blog & Press Pages

Complement Therapeutics Website, Blog & Press Pages - aVenture Research

Library

complementtx.comCrawled Oct 30, 2026

Product

6 pages

Clinical Trials/clinical-trials
Our Research/our-research
Complement Therapeutics studies the complement system’s role in sight-threatening ocular conditions, aiming to identify intervention points that may modify disease progression.
Patient Information/patient-information
CTx001 is an investigational gene therapy currently in clinical development for the treatment of Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).
Platform/platform
Complement Therapeutics has developed a platform focused on targeted modulation of the complement system for ocular disease. The platform is designed to enable precise intervention within complex biological pathways, informed by disease mechanism and clinical relevance.

Blog

1 page

Blog/blog
Complement Therapeutics GmbH (CTx) received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for CTx001, its gene therapy candidate for Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).

Press

6 pages

Complement Therapeutics Announces Completion of Cohort 1 Dosing and Favourable Independent Data Monitoring Committee Recommendation in the Phase I/II Opti-GAIN Study for GA Secondary to AMD/complement-therapeutics-announces-completion-of-cohort-1-dosing-and-favourable-independent-data-monitoring-committee-recommendation-in-the-phase-i-ii-opti-gain-study-for-geographic-atrophy-secondary-t
Complement Therapeutics GmbH (CTx) announced the completion of dosing for Cohort 1 in the Opti-GAIN trial of CTx001 for Geographic Atrophy (GA) secondary to AMD.
Complement Therapeutics Announces Completion of Cohort 2 Dosing and Favourable IDMC Recommendation to Proceed to High Dose and Expansion Cohorts in the Phase I/II Opti-GAIN Study/complement-therapeutics-announces-completion-of-cohort-2-dosing-and-favourable-idmc-recommendation-to-proceed-to-high-dose-and-expansion-cohorts-in-the-phase-i-ii-opti-gain-study
Complement Therapeutics GmbH (CTx) completed dosing in Cohort 2 of the Opti-GAIN Phase I/II trial for CTx001 in patients with Geographic Atrophy (GA) secondary to AMD. The Independent Data Monitoring Committee (IDMC) reviewed safety data for Cohorts 1 and 2, found no significant concerns, and recommended proceeding to Cohort 3.
Complement Therapeutics Announces first patient dosed with CTx001 in the Phase I/II Opti-GAIN study for Geographic Atrophy secondary to AMD/complement-therapeutics-announces-first-patient-dosed-with-ctx001-in-the-phase-i-ii-opti-gain-study-for-geographic-atrophy-secondary-to-amd
Complement Therapeutics GmbH (CTx) dosed the first patient in the Opti-GAIN Phase I/II trial of CTx001 for Geographic Atrophy (GA) secondary to AMD.
Complement Therapeutics Appoints Dr Muhammad Ali Memon FRCOphth, as Chief Medical Officer/complement-therapeutics-appoints-dr-muhammad-ali-memon-frcophth-as-chief-medical-officer

Careers & Hiring

1 page

Careers/careers
Complement Therapeutics is a biotechnology company developing therapies for complement-related diseases, emphasizing scientific rigor and collaboration.

Team

1 page

Board of Directors/board-of-directors
Complement Therapeutics is supported by a syndicate of international investors with expertise across biotechnology, translational science and clinical development.

About

1 page

About Us/about-us
Finance and Legal Administration Manager

Homepage

1 page

Homepage/
Complement Therapeutics is a clinical-stage biotechnology company advancing precision therapies for complement-mediated diseases.